A Form 4 filed with the SEC on September 3, 2026, discloses that Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), sold 10,000 shares of common stock on September 2, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 10,000 shares of common stock disposed of on September 2, 2026.
  • Weighted average price: $80.06 per share, with individual transactions ranging from $80.00 to $80.20.
  • Trading plan: The sale was executed automatically under a Rule 10b5-1 plan adopted by Azamian on December 9, 2025.
  • Post-transaction indirect holdings: 837,991 shares held indirectly through the Bobak Azamian Living Trust, established April 16, 2018.
  • Direct holdings remaining: 33,421 shares held directly following the reported transaction.
  • Filer role: Azamian serves as both a Director and Officer (President/CEO and Board Chair) of the issuer.

Azamian's Share Sale Details and Beneficial Ownership at Tarsus Pharmaceuticals

According to the filing, Bobak R. Azamian disposed of 10,000 shares of Tarsus Pharmaceuticals common stock on September 2, 2026, at a weighted average price of $80.06. The filing notes that the shares were sold in multiple transactions at prices ranging from $80.00 to $80.20, and that Azamian undertakes to provide full details on shares sold at each separate price upon request from the issuer, any security holder, or SEC staff.

The filing discloses that the transaction was effected automatically pursuant to a Rule 10b5-1 trading plan that Azamian adopted on December 9, 2025. The form was signed by Jeffrey Farrow as Attorney-in-Fact on September 3, 2026. The filing also confirms that the box indicating a transaction made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan has been checked.

Following the reported sale, the filing reports that Azamian holds 33,421 shares directly and 837,991 shares indirectly through the Bobak Azamian Living Trust, established April 16, 2018, for which he serves as trustee and holds voting and dispositive power. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The Form 4 reports a single open-market sale of 10,000 common shares by Tarsus Pharmaceuticals' President/CEO and Board Chair on September 2, 2026, executed under a pre-scheduled 10b5-1 plan, with residual direct and indirect beneficial ownership also reported.